Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

Dr. Peter Bach responds to PhRMA’s strong stance in opposition to H.R. 3 Lower Drug Costs Now Act of 2019. The bill proposes to allow Medicare to negotiate the price of selected drugs using 120% of international reference price as the payment upper limit of negotiation. PhRMA neglects to address the pharmaceutical market as a global market in widely circulated talking points, and a deeper analysis proves claims made from the data to be misleading.

Read full editorial here.